Categories: News

Varian Installs Cyclotron for ProBeam Proton Therapy System at Hefei Ion Medical Center in China

PALO ALTO, Calif. and HEFEI, China, April 8, 2019 /PRNewswire/ — Varian (NYSE: VAR) today announced the installation of the cyclotron for the Varian ProBeam® proton therapy system at Hefei Ion Medical Center (HIMC) in China. The cyclotron is a core piece of equipment in the ProBeam proton therapy system, and its installation marks a key milestone for every new proton therapy center. When completed, HIMC will feature three proton therapy treatment rooms with full 360-degree rotational gantries as well as a fixed-beam treatment room and a research room.

Varian’s ProBeam system is the first to offer fully-integrated intensity modulated proton therapy (IMPT) to enable more efficient adaptive proton therapy. Varian’s pencil-beam scanning technology gives clinicians the ability to deliver the dose precisely within the contours of the tumor to minimize dose to healthy tissue. When combined with high quality cone-beam computed tomography (CBCT), the ProBeam system enables sophisticated image guidance during the course of treatment, helping to make it a more precise form of proton therapy. In combination with the ARIA® oncology information system and Eclipse™ treatment planning system, the ProBeam system enables an efficient adaptive workflow.

“We are excited to have achieved this important milestone by successfully installing the cyclotron for the first ProBeam proton therapy system in China,” said Kolleen Kennedy, president, Proton Solutions and chief growth officer, Varian. “We look forward to our continuing partnership with HIMC to complete the construction of this flagship proton center and expand access to this cutting edge  cancer treatment in China.”

“In mainland China there were 3.9 million new cancer cases reported in 2015*, over 10 thousand people are diagnosed with cancer every day, but only one authorized medical center providing particle therapy treatment,” said Li Bing, director of HMIC. “As one of the significant technological innovation programs for Hefei Comprehensive National Science Center, HIMC is proud to have achieved this new important milestone of the cyclotron installation, because it moves us closer to completing the center and achieving our goal of providing this advanced cancer treatment to 2000 patients a year.”

*Report of Cancer Epidemiology in China, 2015, China Journal Oncology, January 2019

About Varian
Varian is a leader in developing and delivering cancer care solutions and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 7,000 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

Press Contact
Mark Plungy
Director, Global Public Relations
+1 (650) 424-5630
mark.plungy@varian.com

Helen Yang
Manager, Greater China Public Relations
+86 (10) 87836354
helen.yang@varian.com

Investor Relations Contact
J. Michael Bruff
Senior Vice President, Investor Relations
+1 (650) 424-5163
investors@varian.com

 

View original content:http://www.prnewswire.com/news-releases/varian-installs-cyclotron-for-probeam-proton-therapy-system-at-hefei-ion-medical-center-in-china-300825703.html

SOURCE Varian

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

28 minutes ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

29 minutes ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

32 minutes ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

32 minutes ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

32 minutes ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…

32 minutes ago